Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus

Influenza A virus (IAV) Infection causes respiratory disease. Recently, Infection of IAV H5N1 among mammals are reported in farmed mink. Therefore, to discover antivirals against IAV, we screened a compound library by using the RNA-dependent RNA polymerase (RdRp) assay system derived from H5N1 IAV including a drug-resistant PA mutant (I38T) and a viral polymerase activity enhancing PB2 mutant (T271A). Upon screening, we found vidofludimus can be served as a potential inhibitor for IAV. Vidofludimus an orally active inhibitor for Dihydroorotate Dehydrogenase (DHODH), a key Enzyme for the cellular de novo pyrimidine biosynthesis pathway. We found that vidofludimus exerted Antiviral activity against wild-type and drug-resistant mutant IAV, with effective concentrations (EC₅₀ ) of 2.10 and 2.11 μM, respectively. The anti-IAV activity of vidofludimus was canceled by the treatment of uridine or cytidine through pyrimidine salvage synthesis pathway, or orotic acid through pyrimidine de novo synthesis pathway. This indicated that the main target of vidofludimus is DHODH in IAV RdRp expressing cells. We also produced recombinant seasonal IAV H1N1 virion and influenza B virus (IBV) RdRp assay system and confirmed vidofludimus also carried highly Antiviral activity against seasonal IAV and IBV. Vidofludimus is a candidate drug for the future threat of IAV H5N1 Infection among humans as well as seasonal Influenza Virus infection.

H5N1; RdRp; baloxavir marboxil resistance; favipiravir; highly pathogenic; influenza virus; vidofludimus.